The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
High-potency cannabis and the risk of psychosis
Open accessAbstract
Background: People who use cannabis have an increased risk of psychosis an effect attributed to the active ingredient δ9-tetrahydrocannabinol (Δ9-THC). There has recently been concern over an increase in the concentration of Δ9-THC in the cannabis available in many countries. Aims: To investigate whether people with a first episode of psychosis were particularly likely to use high-potency cannabis. Method: We collected information on cannabis use from 280 cases presenting with a first episode of psychosis to the South London & Maudsley National Health Service (NHS) Foundation Trust, and from 174 healthy controls recruited from the local population. Results: There was no significant difference between cases and controls in whether they had ever taken cannabis, or age at first use. However, those in the cases group were more likely to be current daily users (OR = 6.4) and to have smoked cannabis for more than 5 years (OR = 2.1). Among those who used cannabis, 78% of the cases group used high-potency cannabis (sinsemilla, ‘skunk’) compared with 37% of the control group (OR 6.8). Conclusions: The finding that people with a first episode of psychosis had smoked higher-potency cannabis, for longer and with greater frequency, than a healthy control group is consistent with the hypothesis that Δ9-THC is the active ingredient increasing risk of psychosis. This has important public health implications, given the increased availability and use of high-potency cannabis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We provide a weak recommendation against the use of cannabinoids in neuropathic pain, mainly because of negative results, potential misuse, abuse, diversion and long term mental health risks particularly in susceptible individuals.66–71”
From Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis (2015) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300496 · Cited by 1,024
Psychosis Screening Questionnaire
Bebbington, P., & Nayani, T. (1995) · PsycTESTS Dataset · doi:10.1037/t30040-000 · Cited by 546
From dopamine to salience to psychosis—Linking biology, pharmacology and phenomenology of psychosis
Kapur, S., Mizrahi, R., & Li, M. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.01.003 · Cited by 512
The Environment and Schizophrenia: The Role of Cannabis Use
Henquet, C. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi027 · Cited by 468
Cannabis, the mind and society: the hash realities
Murray, R. M., Morrison, P. D., Henquet, C., & Forti, M. D. (2007) · Nature reviews. Neuroscience · doi:10.1038/nrn2253 · Cited by 329
Self-citationEffects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
Morgan, C. J. A., & Curran, H. V. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.046649 · Cited by 300
Self-citationΔ9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum
Bossong, M., van Berckel, B. N., Boellaard, R., Zuurman, L., Schuit, R., Windhorst, A., van Gerven, J. V., Ramsey, N., Lammertsma, A., & Kahn, R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.138 · Cited by 262
Potter, D. J., Clark, P., & Brown, M. B. (2008) · Journal of Forensic Sciences · doi:10.1111/j.1556-4029.2007.00603.x · Cited by 230
Cannabis-Induced Psychosis-Like Experiences Are Associated with High Schizotypy
Barkus, E., Stirling, J., Hopkins, R., & Lewis, S. W. (2006) · Psychopathology · doi:10.1159/000092678 · Cited by 170
Research works printed but not linked: 5
- 2005, The Classification of Cannabis under the Misuse of Drugs Act 1971
- 1992, Schedules for Clinical Assessment in Neuropsychiatry (SCAN)
- 1992, The ICD–10 Classification of Mental and Behavioural Disorders. Clinical Description and Diagnostic Guidelines
- British Crime Survey, 2006–2007
- Hardwick, 2008, Home Office Cannabis Potency Study
Cited by
Sorted by citations
Items 301–400 of 563
Rodríguez, V., Alameda, L., Aas, M., Gayer-Anderson, C. E., Trotta, G., Spinazzola, E., Quattrone, D., Tripoli, G., Jongsma, H. E., Stilo, S. A., et al. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae207 · Cited by 13
Self-citationLodhi, R. J., Wang, Y., Rossolatos, D., MacIntyre, G., Bowker, A., Crocker, C. E., Ren, H., Dimitrijević, A., Bugbee, D. A., Loverock, A., et al. (2017) · Brain and Behavior · doi:10.1002/brb3.850 · Cited by 12
Ayonrinde, O. (2019) · Psychological Medicine · doi:10.1017/s0033291719001077 · Cited by 13
Núñez, C., Ochoa, S., Huerta‐Ramos, E., Baños, I., Barajas, A., Dolz, M., Sánchez, B., Cacho, N. D., & Usall, J. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.05.017 · Cited by 12
Reward, Control & Decision-Making in Cannabis Use Disorder: Insights from Functional MRI
Fatima, H., Howlett, A. C., & Whitlow, C. T. (2019) · British Journal of Radiology · doi:10.1259/bjr.20190165 · Cited by 13
Rognli, E. B., Bramness, J. G., & von Soest, T. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13104 · Cited by 12
Stem Cells for Improving the Treatment of Neurodevelopmental Disorders
Donegan, J. J., & Lodge, D. J. (2020) · Stem Cells and Development · doi:10.1089/scd.2019.0265 · Cited by 13
Pauselli, L., Birnbaum, M. L., Jaime, B. P. V., Paolini, E., Kelley, M. E., Broussard, B., & Compton, M. T. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.01.020 · Cited by 13
Penttilä, M. (2013) · Cited by 11
Bear, D., Hosker-Field, A. M., Westall, K., D'Alessio, H., & Cresswell, M. (2024) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2024.104514 · Cited by 11
Hájková, M., Knížková, K., Siroňová, A., Keřková, B., Jonáš, J., Šustová, P., Dorazilová, A., & Rodríguez, M. (2021) · Cognitive Neuropsychiatry · doi:10.1080/13546805.2021.1924649 · Cited by 11
Katapally, T. R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263533 · Cited by 11
Johnstad, P. G. (2022) · Drug Science Policy and Law · doi:10.1177/20503245221095228 · Cited by 12
Pow, J. L., Donald, C., Forti, M. D., Roberts, T., Weiss, H. A., Ayinde, O. O., John, S., Olley, B., Ojagbemi, A., Esponda, G. M., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291723000399 · Cited by 11
Self-citationBeyond the Binary: Gender Inclusivity in Schizophrenia Research
Nolan, C. J., Roepke, T. A., & Perreault, M. L. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.03.018 · Cited by 14
Alcover, K. C., Oluwoye, O. A., Kriegel, L. S., McPherson, S., & McDonell, M. G. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.07.014 · Cited by 11
Enhancement drugs: are there limits to what we should enhance and why?
Hesse, M. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-50 · Cited by 11
Symptomatic Predictors of Suicidal Behavior in Early Psychosis: Systematic Review
Ricci, V., Sarni, A., Berardis, D. D., Fraccalini, T., Martinotti, G., & Maina, G. (2025) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000860 · Cited by 10
Toll, A., Bergé, D., Burling, K., Scoriels, L., Treen, D., Monserrat, C., Màrmol, F., Durán, X., Jones, P. B., Pérez, V., et al. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01117-y · Cited by 10
Sainz-Cort, A., Jiménez-Garrido, D. F., Marrón, E. M., Viejo-Sobera, R., Heeroma, J. H., & Bouso, J. C. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0037 · Cited by 10
Ferraro, L., Murray, R. M., Forti, M. D., Quattrone, D., Tripoli, G., Sideli, L., Barbera, D. L., & Cascia, C. L. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.06.004 · Cited by 10
Self-citationCannabis industry and medical cannabis clinics need regulation.
Kahan, M., Srivastava, A., & Clarke, S. (2019) · Europe PMC (PubMed Central) · Cited by 10
Epidemiology of adolescent substance use in Norfolk schools
Roderick, E., Penney, J., Murrells, T., Dargan, P. I., & Norman, I. J. (2018) · QJM · doi:10.1093/qjmed/hcy153 · Cited by 10
The Relationship between Cannabidiol and Psychosis: A Review
Silva, T. B. G., Balbino, C. Q., & Weiber, A. F. M. (2015) · Annals of Clinical Psychiatry · doi:10.1177/104012371502700208 · Cited by 10
Oh, H. Y., Koyanagi, A., Singh, F., & DeVylder, J. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.09.008 · Cited by 10
Hames, A., Evangeli, M., Harrop, C. E., & Forti, M. D. (2011) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2011.00316.x · Cited by 10
Forti, M. D., Bond, B. W., Spinazzola, E., Trotta, G., Lynn, J., Malkin, R., Siddiqui, N. K., Demir, S., Opadokun, T., Leung, P. B. M., et al. (2024) · BJPsych Open · doi:10.1192/bjo.2024.782 · Cited by 9
Self-citationBrink, V., Andleeb, H., Gayer-Anderson, C. E., Arango, C., Arrojo, M., Berardi, D., Bernardo, M., Bobes, J., Del‐Ben, C. M., Ferraro, L., et al. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae072 · Cited by 9
Self-citationDonoghue, K., Mazzoncini, R., Hart, J., Zanelli, J., Morgan, C., Dazzan, P., Morgan, K. D., Murray, R. M., Jones, P. B., & Doody, G. A. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01803.x · Cited by 9
Self-citationNeurotrophic Factors in Cannabis-induced Psychosis: An Update
Ricci, V., Berardis, D. D., Martinotti, G., & Maina, G. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230829152150 · Cited by 9
Sexual dysfunction and central obesity in patients with first episode psychosis
Theleritis, C. G., Bonaccorso, S., Habib, N., Stahl, D. R., Gaughran, F., Vitoratou, S., Atakan, Z., Kolliakou, A., Gardner-Sood, P., Dazzan, P., et al. (2017) · European Psychiatry · doi:10.1016/j.eurpsy.2016.11.008 · Cited by 9
Self-citationCANNABIS USE AND SUICIDE IN NON-AFFECTIVE PSYCHOSIS: A MINI-REVIEW OF RECENT LITERATURE
Ricci, V., Cristofori, E., Passarello, E., Paggi, A., Cavallo, A., Ceci, F., Martinotti, G., Berardis, D. D., & Maina, G. (2023) · Psychiatria Danubina · doi:10.24869/psyd.2023.307 · Cited by 8
Joshi, S., Snyder, K. M., Thurstone, C., Rivera, B. D., Feldman, J. M., Cerdá, M., & Krawczyk, N. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112719 · Cited by 8
Alghamdi, W., Stamate, D., Katherine, V., Stahl, D. R., Colizzi, M., Tripoli, G., Quattrone, D., Ajnakina, O., Murray, R. M., & Forti, M. D. (2016) · International Conference on Machine Learning and Applications · doi:10.1109/icmla.2016.0148 · Cited by 8
Self-citationTheunissen, E. L., Kuypers, K. P. C., Mason, N. L., & Ramaekers, J. G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.891811 · Cited by 8
van Hooijdonk, C. F. M., van der Pluijm, M., de Vries, B. M., Cysouw, M. C. F., Alizadeh, B. Z., Simons, C. J. P., van Amelsvoort, T., Booij, J., Selten, J., de Haan, L., et al. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.10.030 · Cited by 8
L’impact du cannabis à l’adolescence sur la transition psychotique de l’adulte
Krebs, M., Gut, A., Plaze, M., & Dervaux, A. (2013) · Neuropsychiatrie de l Enfance et de l Adolescence · doi:10.1016/j.neurenf.2013.03.001 · Cited by 8
Guo, Z., Tse, Y. C., Zhang, Y., Sun, Q., Vecchiarelli, H. A., Aukema, R. J., Hill, M. N., Wong, T. P., & Boksa, P. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.09.003 · Cited by 9
Coutinho, L., Honorato, H., Higuchi, C. H., Cavalcante, D. A., Belangero, S. I., Noto, M. N., Bressan, R. A., Cordeiro, Q., Noto, C. D. S., & Gadelha, A. (2018) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2018.10.002 · Cited by 8
Latent inhibition, aberrant salience, and schizotypy traits in cannabis users
Dawes, C., Quinn, D., Bickerdike, A., O’Neill, C., Granger, K. T., Pereira, S. C., Mah, S. L., Haselgrove, M., Waddington, J. L., O’Tuathaigh, C. M. P., et al. (2022) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2021.100235 · Cited by 9
Tchuente, V., Sheehy, O., Zhao, J., Gorgui, J., Sandoval, Y.-H. G., & Bérard, A. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-052220 · Cited by 8
Gaughran, F., Stahl, D. R., Patel, A. K., Ismail, K., Smith, S. M., Greenwood, K., Atakan, Z., Gardner-Sood, P., Stringer, D., Hopkins, D., et al. (2020) · Programme Grants for Applied Research · doi:10.3310/pgfar08010 · Cited by 9
Self-citationEffects of Cannabis Use on Human Behavior—Reply
Volkow, N. D. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.1332 · Cited by 8
Sharma, P., Matthews, D. B., Nguyen, Q. A., Rossmann, G. L., Patten, C. A., & Hammond, C. J. (2023) · Clinical Medicine Insights Pediatrics · doi:10.1177/11795565231162297 · Cited by 7
Cognitive test performance in chronic cannabis flower users, concentrate users, and non-users
Cuttler, C., Petrucci, A. S., & LaFrance, E. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-35217-1 · Cited by 7
Measuring Interstate Variations in the Consequences of Illegal Drugs: A Composite Indicator Approach
Sevigny, E. L., & Saisana, M. (2015) · Social Indicators Research · doi:10.1007/s11205-015-1042-2 · Cited by 7
Do the effects of cannabis on the hippocampus and striatum increase risk for psychosis?
Daniju, Y., Bossong, M. G., Brandt, K. R., & Allen, P. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.02.010 · Cited by 7
Livne, O., Budney, A. J., Borodovsky, J. T., Shmulewitz, D., Walsh, C. A., Struble, C. A., Habib, M. I., Aharonovich, E., & Hasin, D. S. (2024) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2024.2309340 · Cited by 7
To legalize cannabis in Ghana or not to legalize? Reviewing the pharmacological evidence
Mensah, K. B., & Adu-Gyamfi, P. K. T. (2019) · Archives of Pharmacy and Pharmaceutical Sciences · doi:10.29328/journal.apps.1001018 · Cited by 7
Gostoli, S., Fantini, L., Casadei, S., Angelis, V. A. D., & Rafanelli, C. (2020) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2020.1799942 · Cited by 7
Cannabinoids and Brain Damage: A Systematic Review on a Frequently Overlooked Issue
Scopetti, M., Morena, D., Manetti, F., Santurro, A., Fazio, N. D., D’Errico, S., Padovano, M., Frati, P., & Fineschi, V. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023666220614145535 · Cited by 7
Medical marijuana: a public health perspective
Desai, U., & Patel, P. (2013) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20130305 · Cited by 7
Ethnic minority position as risk indicator for autism-spectrum and psychotic disorders
van der Ven, E. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20160422ev · Cited by 7
From heavy cannabis use to psychosis: is it time to take action?
Johnson‐Ferguson, L., & Forti, M. D. (2021) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2021.33 · Cited by 7
Is cannabis responsible for early onset psychotic illnesses?
Dervaux, A., Krebs, M., & Laqueille, X. (2011) · Neuropsychiatry · doi:10.2217/npy.11.31 · Cited by 5
Nimgaonkar, V. L., Dickerson, F., Pouget, J. G., Chowdari, K. V., O’Dushlaine, C. T., Wood, J. A., Klei, L., Devlin, B., & Yolken, R. H. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.12.025 · Cited by 6
Spinazzola, E., Quattrone, D., Rodríguez, V., Trotta, G., Alameda, L., Tripoli, G., Gayer-Anderson, C. E., Freeman, T. P., Johnson, E. C., Jongsma, H. E., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291723001071 · Cited by 6
Self-citationCharacteristics of Cannabis-Only and Other Drug Users Who Visit the Emergency Department
Woodruff, S. I., McCabe, C. T., Hohman, M. M., Clapp, J. D., Shillington, A. M., Eisenberg, K., Sise, C. B., Castillo, E. M., Chan, T. C., & Sise, M. J. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2016.0012 · Cited by 6
Santos-Álvarez, I., Pérez‐Lloret, P., González‐Soriano, J., & Moreno, M. P. (2021) · Adicciones · doi:10.20882/adicciones.1630 · Cited by 6
Spinazzola, E., Degen, H., Austin-Zimmerman, I., Trotta, G., Chesney, E., Li, Z., Alameda, L., Leung, B. M., Lang, Y., Quattrone, A., et al. (2025) · BMJ Mental Health · doi:10.1136/bmjment-2025-301810 · Cited by 5
Self-citationWest, M. L., & Sharif, S. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.03.006 · Cited by 5
Toftdahl, N. G., Nordentoft, M., & Hjorthøj, C. R. (2016) · Journal of Dual Diagnosis · doi:10.1080/15504263.2016.1176426 · Cited by 5
Loureiro, C. M., Zuelli, F. M. D. G. C., Fachim, H., Shuhama, R., de Oliveira, A. M., Menezes, P. R., Dalton, C., Louzada‐Júnior, P., Belangero, S. I., Coeli‐Lacchini, F. B., et al. (2023) · Brazilian Journal of Psychiatry · doi:10.47626/1516-4446-2022-2882 · Cited by 5
Which cannabis users develop psychosis?
Forti, M. D., Henquet, C., Verdoux, H., Murray, R. M., & van Os, J. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511706080.013 · Cited by 5
Self-citationA Review on the Impact of Cannabis in Society and the Analytical Methodologies for Cannabinoids
Vergne, M. J., Reynolds, L. J., Brown, A., Pullias, G., & Froemming, A. (2023) · Psychoactives · doi:10.3390/psychoactives2010003 · Cited by 5
Gilman, J. M., Sobolewski, S. M., & Evins, A. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804791-0.00010-0 · Cited by 6
More harm than good? Cannabis, harm and the misuse of drugs act
Potter, G., & Wells, H. (2021) · Drugs and Alcohol Today · doi:10.1108/dat-09-2021-0047 · Cited by 4
Buschner, M., Heckel, N., Duerler, P., Engeli, E. J. E., Schneider, S., Havelka, E. M., Nordt, C., & Herdener, M. (2024) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2024.104610 · Cited by 4
Greer, D., Atherton, J., & Girgis, J. (2025) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70060 · Cited by 4
Ganesh, S., Cortes-Briones, J., Martin, A. M. S., Skosnik, P. D., D’Souza, D. C., & Ranganathan, M. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0166 · Cited by 4
Dellazizzo, L., Potvin, S., Giguère, S., & Dumais, A. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0163 · Cited by 4
Snooks, T., Stewart, S. H., Romero‐Sanchiz, P., DeGrace, S., Barrett, S. P., Bernusky, H. C. R., & Tibbo, P. G. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107586 · Cited by 4
Psychosis relapse, medication non-adherence, and cannabis
Engh, J. A., & Bramness, J. G. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30254-7 · Cited by 4
Putative Role of Endocannabinoids in Schizophrenia
Leweke, F. M., & Rohleder, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809666-6.00004-6 · Cited by 4
Suetani, S., & Vancampfort, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812605-9.00004-6 · Cited by 4
Mader, J., Smith, J. M., Smith, J. D., & Christensen, D. R. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-032651 · Cited by 4
Mason, A., Sami, M. B., Notley, C. J., & Bhattacharyya, S. (2021) · Journal of Cannabis Research · doi:10.1186/s42238-021-00065-1 · Cited by 4
Sharma, P., Riehm, K. E., Young, A. S., Reynolds, M., Tarter, R. E., Horner, M. S., & Hammond, C. J. (2021) · Substance Use & Misuse · doi:10.1080/10826084.2021.1964086 · Cited by 4
Sulley, S., Ndanga, M., & Saka, A. K. (2022) · Cureus · doi:10.7759/cureus.28361 · Cited by 4
Fekih‐Romdhane, F., Alhuwailah, A., Shuwiekh, H. A. M., Stambouli, M., Hakiri, A., Cheour, M., Loch, A. A., & Hallit, S. R. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05727-x · Cited by 4
Preadult polytoxicomania—strong environmental underpinnings and first genetic hints
Steixner-Kumar, A. A., Gastaldi, V. D., Seidel, J., Rosenberger, A., Begemann, M., & Ehrenreich, H. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01069-2 · Cited by 4
Stager, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0755-7.00108-1 · Cited by 4
Ricci, V., Sarni, A., Barresi, M., Remondino, L., Martinotti, G., & Maina, G. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104624 · Cited by 3
Marinello, S. (2023) · Journal of Drug Issues · doi:10.1177/00220426231159542 · Cited by 3
Marinello, S. (2024) · Cannabis · doi:10.26828/cannabis/2024/000224 · Cited by 3
Iyegbe, C. O., Modinos, G., & Rivera, M. (2012) · InTech eBooks · doi:10.5772/36075 · Cited by 3
The need for close monitoring of early psychosis and co-occurring substance misuse
Caton, C. L. M. (2011) · The Psychiatrist · doi:10.1192/pb.bp.110.032342 · Cited by 3
Cannabis and Psychosis: A Review of the Risk Factors Involved
Amar, M. B. (2020) · American Journal of Plant Sciences · doi:10.4236/ajps.2020.1112139 · Cited by 3
Cannabis Use, Schizotypy and Kamin Blocking Performance
Dawes, C., Bickerdike, A., O’Neill, C., Pereira, S. C., Waddington, J. L., Moran, P. M., & O’Tuathaigh, C. M. P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.633476 · Cited by 3
Archie, S., Palaniyappan, L. K., Olagunju, A. T., Johnson, N., Kozloff, N., Sadeh, E., Bardell, A., Baines, A., Anderson, K. K., Ayonrinde, O., et al. (2022) · JMIR Research Protocols · doi:10.2196/36758 · Cited by 3
Thiagarajan, S. K., Mok, S. Y., Ogawa, S., Parhar, I. S., & Tang, P. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044088 · Cited by 3
Weinstein, A. M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1230760 · Cited by 4
Does cannabis use cause schizophrenia? The epidemiological evidence
Zammit, S., Arseneault, L., & Murray, R. M. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511706080.016 · Cited by 3
Self-citationLe cannabis et ses effets délétères : pour un débat plus nuancé
Jobidon, L., & Jutras‐Aswad, D. (2018) · Drogues santé et société · doi:10.7202/1044306ar · Cited by 3
Roser, P. (2019) · Forensische Psychiatrie Psychologie Kriminologie · doi:10.1007/s11757-019-00543-6 · Cited by 3
Jalali, S. (2013) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2013/6192 · Cited by 3
Increasing Plant Concentrations of THC and Implications on Health Related Disorders
Vindenes, V., & Mørland, J. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00004-1 · Cited by 3
The impact of peri-natal stress on psychosis risk: results from the Bo-FEP incidence study
Matteis, T. D., D’Andrea, G., Lal, J., Berardi, D., & Tarricone, I. (2020) · BMC Research Notes · doi:10.1186/s13104-020-04992-9 · Cited by 3
The potency of THC in Cannabis products.
Arnold, C. (2011) · Cited by 3
Schecter, D., & Cyr, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-89918-9_7 · Cited by 3
Metadata
- Authors
- Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., Butt, A., Stilo, S. A., Wiffen, B., Powell, J., & Murray, R. M.
- Affiliations
- Springfield University Hospital (GB)
- ORCID
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2009-12
- Volume
- 195
- Issue
- 6
- Pages
- 488-491
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- PMC
- PMC2801827
- OpenAlex
- W2104532446
- Cited by
- 567
- References
- 15
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 25 · 2023: 30 · 2022: 38 · 2021: 41 · 2020: 54 · 2019: 31 · 2018: 35 · 2017: 38 · 2016: 46 · 2015: 36 · 2014: 28 · 2013: 36 · 2012: 29
- FWCI
- 25.87
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The British Journal of Psychiatry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- King's College London
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- high-potency cannabis, psychosis, first-episode psychosis, delta-9-tetrahydrocannabinol, cannabis use, daily cannabis use, public health implications
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Cannabis, Female, Humans, London, Male, Marijuana Smoking, Middle Aged, Psychoses, Substance-Induced, Risk Factors, Dronabinol, Case-Control Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
